Radioligand Therapy Product Design: From Concept to the Clinic – Accelerating Safe & Effective Clinical Translation
10:30 am - Wednesday 25th February 2026
- Selecting vector, linker, and radionuclide to maximize tumour specificity, retention, and therapeutic index
- Preclinical and manufacturing considerations to ensure scalability, consistency, and early risk reduction
- Achieving the optimal clinical target product profile to drive efficacy, safety, and competitive differentiation in the clinic
New Company for 2026
